


Consider the KICK-1 Study

The KICK-1 Study is a clinical trial testing oral difelikefalin to see if it helps reduce the intensity of itching and the impact that itching has on your quality of life. The oral form of difelikefalin is considered an investigational drug at this time because that form of medication has not been approved by the FDA.

An intravenous (IV) form of difelikefalin has been approved by the FDA to treat itching associated with CKD in adults who are undergoing dialysis. The KICK-1 Study will evaluate the medication in its oral (tablet) form to see if it reduces the itching in CKD patients who are not on dialysis.

Please speak with a study team member to learn more about the KICK-1 Study.

For more information about the KICK-1 Study, please contact:



Living with
CKD and
looking for
potential relief
from itch?

Consider taking part
in a study of new
investigational
study medication



About the KICK-1 Study

The KICK-1 Study is a clinical trial testing oral difelikefalin to see if it helps reduce the intensity of itching and the impact that itching has on your quality of life. The oral form of difelikefalin is considered an investigational drug at this time because that form of medication has not been approved by the FDA.

Participants in the KICK-1 study will be randomly assigned (like the flip of a coin) to receive one tablet of delikefalin or placebo daily. A placebo looks like the investigational medication but does not contain any active ingredients.

Neither you nor the study team will know whether you received delikefalin or placebo and will not be able to choose which you receive.

What to Expect?

The KICK-1 study, which will last up to 70 weeks, includes:

- **Screening and run-in period:** up to 4 weeks
- **Treatment period:** 12 weeks
- **Extension treatment period:** up to 1 year

Participation in the study involves approximately 14 site visits and two telephone follow-up calls.

Who Can Participate?

You may be eligible to participate in the KICK-1 study if you:

- Are between 18 to 85 years of age
- Have been diagnosed with chronic kidney disease
- Are not currently on dialysis
- Have been experiencing daily or near daily itching for at least 6 months
- Have experienced an inadequate response to current or prior topical treatments (including emollients) for itching

Other criteria will need to be met to confirm your eligibility for the KICK-1 study.

Why Take Part?

We cannot promise that participants who have CKD-associated itching will receive any direct benefits from the KICK-1 Study. However, the possible benefits of taking part in the KICK-1 Study may include:

- Improved symptoms of itching
- Close care and monitoring of health and symptoms of itching
- Helping doctors learn more about itching associated with CKD, which may help others in the future

About Clinical Studies

A clinical research study is carefully supervised research that is done before a study drug or other investigational product is made available to the public.

- Clinical studies follow specific rules to protect the rights, safety, well-being, and confidentiality of study participants
- The results help government regulators decide if a medication or product is safe and should be made available to patients
- Clinical trials are the only way to develop new medical treatments to improve patient care

Participation in the KICK-1 Study is completely voluntary. If you choose to take part, you can change your mind and withdraw at any time without giving a reason. If you decide not to participate, it will not affect your medical care now or in the future.

